The US market for PV devices is an evolving market, where a large undiagnosed patient population and innovative product launches will allow for significant expansion through 2025.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in the US across a 10-year period.
Questions Answered in This Report:
- Peripheral DCBs have experienced strong growth in the year following their commercial launch.
- To what degree will DCBs be adopted in the US over the forecast period?
- How will DCB uptake affect other PV devices such as stents, normal balloon catheters, and atherectomy devices?
- Will the emergence of DCBs have an impact on recently established DES usage?
- Which new indications will drive growth in the DCB market?
- A focus on noninvasive lower-extremity revascularization will contribute to increasing endovascular procedure volumes.
- How will the adoption of and familiarity with CTO crossing devices affect the fem-pop and infrapop device markets?
- How has CMS reimbursement affected the use of atherectomy?
- What impact will the rising role of office-based procedures have on the lower-extremity market?
- A number of aortic stent graft innovations will expand the treatable patient population and drive market growth.
- To what extent will endovascular procedures penetrate aortic repairs through 2025?
- How will the upcoming cohort of fenestrated and branched grafts impact the stent graft market?
- How will new entrants to the aortic stent graft market alter the competitive landscape, which has historically been dominated by Medtronic, W. L. Gore, and Cook Medical?